GREENFIELD, Ind., May 24, 2017 – Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), today announced that it received a grant from the Bill & Melinda Gates Foundation to provide sustainable development solutions to address food insecurity in East African countries. The commitment will work to improve animal health and productivity in dairy herds and poultry flocks for smallholder farms in Kenya, Uganda and Tanzania.
Brussels, 26 June 2017 –Healthy animals mean healthy people and a healthy planet. Elanco Animal Health and eight other organisations* working in the farm sector today launched a call for key players help to foster innovation in Europe’s agriculture and rural areas and to enhance their sustainability.
Basel, Switzerland – Conflicting sources of information about how our food is produced make it difficult for families to make smart choices about nutrition and health, according to a new study from the ENOUGH movement, carried out in 11 countries globally, including countries in Europe. The consumer survey measured understanding and knowledge of popular food and nutrition topics including product labels, farming methods, nutritional value and environmental impacts.
Elanco, the leading animal health and science-based innovation company today announced the winner of its human-pet bond photography competition. As part of Elanco’s commitment to help pets live longer, healthier and higher-quality lives, the winning images are being displayed at a special exhibition at its EMEA headquarters in Basel, Switzerland.
Elanco, the leading animal health and science-based innovation company today announced the launch of its second European, South Africa, Russia and Turkey-wide photography competition – this year focusing on the human-pet bond.
Elanco360° - produced and curated by Elanco Animal Health in Europe – features contributions from across the continent and promises ‘new perspectives on the animal health agenda’, with content on food sustainability, animal welfare and the bond between people and their pets. Elanco’s vice-president for Europe, Middle East and Africa Ramiro Cabral said the new blog will be a unique opportunity to share and shape thought and ideas across the animal health community.
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), announces the opening of a state-of-the-art Vaccines Innovation Center whose intentional design will enable scientists to address some of animal health’s most pressing issues. Half of the 48,000 sq. foot space comprises an open concept collaboration environment intentionally designed to encourage scientific interaction. The remaining floor area houses an integrated laboratory space equipped with the very latest technology in the fields of immunology, molecular biology and microbiology.
Elanco announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry.
At the end of the consultation period started on 21 October, 2015 and after careful examination of all formal proposals, Elanco announced it will move forward with its proposal to transition a set of core capabilities to Elanco’s regional headquarters in Basel, and its facilities in St. Aubin will be closed. In total, 27 employees will be offered the opportunity to transfer to new laboratories in Basel. In addition, at least five new positions will be created in Basel and offered to qualified employees from St. Aubin on a priority basis. For all other employees, the company has developed a robust social plan. As of today, Elanco has identified appropriate locations for a vast majority of the animals which are affected by the closure of the site in St. Aubin, including adoption by employee pet owners.
With an estimated 60% increase in global demand for high quality protein such as milk, meat and eggs by 2050, the question about Europe’s role in helping address that demand cannot remain unanswered. The challenge is multifaceted: we must produce quantities of livestock food products through systems that are resource-efficient, climate-friendly, socially responsible, and economically viable for both European farmers and consumers.
A new survey commissioned by Elanco’s ENOUGH Movement and conducted by SWG on 2,000 people across Italy, Germany, France and UK, shows that – based on their own general perception on food habits and behaviours as well as of their countrymen – about 50% of the interviewees say they cannot follow a sufficiently varied nutritional diet. In particular, fish, beef and pork are among foods often absent from people’s diet.
Elanco announces an agreement to acquire Lohmann Animal Health, a privately-held company headquartered in Cuxhaven, Germany. The acquisition will establish Elanco as a global poultry leader, extending our presence into layers and expanding our growing vaccine presence.
Innovation, Choice and Trade - the Three Pillars for Ensuring a Food Secure World before 2050
The report, written by Elanco President Jeff Simmons, advocates for farmer access to innovative tools in order to feed a growing global population and save natural resources.
Elanco conducted the second edition (2013) of the International Consumer Attitudes Study to determine the key issues for consumers when buying food. Based on two key criteria – 1) unaided questions and 2) consumer spending data, the research includes 34 studies from 26 countries accounting for more than 100,000 consumers.
For more information, visit www.enoughmovement.com. Join @JeffSimmons2050 and @Elanco for more discussion on Twitter with #FeedThe9. The website calls for advocates to join The Enough Movement and provides resources for campaigners to help make their voices heard in the fight for a food secure tomorrow.
Elanco announces an agreement to acquire Novartis Animal Health, creating a global leader in animal health innovation and customer value. The $5.4 billion deal creates world’s second-largest animal health company.
LEAWOOD, Kan. (U.S.) (For EU audience), November 10, 2017 — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Medicine Agency’s (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion to recommend the marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union. Following the positive opinion, the European Commission will complete the regulatory process for a final decision on the Marketing Authorisation in early 2018.
LEAWOOD, Kan. (U.S.) (For EU audience), January 11, 2018 — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.
Greenfield (IN), U.S., 20th March 2018 - Elanco Animal Health, together with the COAST Development Group, today announce the publication of a proposal for a practical diagnostic aid, called ‘COAST’ (Canine OsteoArthritis Staging Tool) – A tool expected to improve the diagnosis and monitoring of dogs with osteoarthritis with the potential to guide disease management plans.
Greenfield, Ind. (January, 2018) – Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), received two of the top honors in both food and companion animal innovation from Animal Pharm, a leading industry publication. During the 2017 award cycle, Galliprant (grapiprant tablets) was named Animal Pharm’s Best Companion Animal Product and Clynav took top honors as Best Food Animal Product.
GREENFIELD, IND. (February 13, 2018) – One of the most discussed – and surprisingly divisive – topics today is agriculture and how our food is raised. GMOs, organic, cage-free: academics and activists alike are looking for the magic recipe to produce enough food for the growing population while safeguarding human health, animal welfare and the environment.
GREENFIELD, IND. (January 25, 2018) – Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), is pleased to announce a new global in-licensing agreement with Ab E Discovery to further develop and bring to market an egg antibody focused on supporting gut health, and thereby the growth and welfare, of poultry.
Greenfield (IN), U.S., (May 23, 2018) – Elanco Animal Health, a division of Eli Lilly and Company (NYSE:&LLY), and Heifer International mark a 10-year milestone in their journey that shares the upcoming World Hunger Day mission – empowering people to create a food secure world. Since 2008, Elanco and its employees have joined forces to give nearly $5 million to Heifer International’s efforts to achieve food security across the globe.
INDIANAPOLIS, IND. (July 24, 2018) – Eli Lilly and Company (NYSE: LLY) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.S. Securities and Exchange Commission (SEC) for a potential initial public offering (IPO) of a minority ownership stake in Elanco as a separate company.
The offering is expected to represent an ownership stake of less than 20 percent. The number of shares to be offered and the price range for the offering have not yet been determined. The company expects to complete the IPO process during the second half of 2018.
[Greenfield, Ind., October 16, 2018] - Elanco Animal Health Incorporated (NYSE:ELAN) is progressing a groundbreaking project to provide sustainable development solutions to address food insecurity in East African countries – Tanzania, Kenya and Uganda. The East Africa Growth Accelerator (EAGA) is Elanco’s first pure ‘Shared Value’ project, which is made possible through a $3.1 million grant from the Bill & Melinda Gates foundation. The grant enables the registration, manufacturing and distribution of affordable high-quality veterinary products, along with intensive training initiatives for smallholder farmers and channel partners.
[Basel, Switzerland (29 November 2018)]: Elanco Animal Health Incorporated (NYSE:ELAN) and Farm Radio International (FRI) have partnered to produce a 13-week series of radio programs designed to support and educate small-scale livestock farmers in North Tanzania to manage the challenges around livestock health and wellbeing, supporting a drive to greater food security, livestock health and care in the region.
At the 2018 European Veterinary Dermatology Congress, co-organized by ESVD ECVD, Elanco Animal Health Incorporated (NYSE:ELAN) conducted a survey to identify the challenges and needs of veterinarians when treating otitis externa in dogs.
Basel, Switzerland (March 12, 2019) Elanco Animal Health Incorporated (NYSE: ELAN) recently announced that it is now a fully independent company, becoming the second largest exclusively dedicated animal health company in the world. Last September, Elanco listed on the New York Stock Exchange and on March 11 Eli Lilly and Company, Elanco´s former parent company, completed the divestiture of its ownership. This completes the journey Elanco began in 2017, when Lilly first announced potential strategic alternatives for the 64-year-old animal health company.
Nairobi, Kenya 26TH MARCH 2019 - Elanco Animal Health Incorporated (NYSE: ELAN) in partnership with Ultravetis East Africa Ltd. has launched an animal feed additive aimed at increasing milk production in Kenya.
The additive, Rumensin™ 200 will be used by animal feed manufacturers in Kenya to fortify dairy feed, enabling dairy cows generate more energy and have better food absorption to increase milk production.
Dar-es Salaam June 22nd 2019 Elanco Animal Health Incorporated (NYSE:ELAN) has launched a 12-week series of radio programming on animal health in Northern, Coast and Western Tanzania, as an expansion of the current partnership with Farm Radio International (FRI).
Greenfield, ID., U.S., August 20th 2019 ….Deal strengthens and accelerates Elanco’s Innovation, Portfolio, and Productivity (IPP) strategy, creating second largest animal health leader by global revenue
The blue Elanco logo is the prefered version to use in our materials.
The 1-Color black logo may be used on a white background when applications require a mark in black or do not allow for full color
The 1-Color white logo may be used when a background does not provide sufficient contrast for any of the full color or 1-color black logos. The preference is to use this logo on an Elanco Blue background. When use of Elanco Blue is prohibited, this logo may be placed on any solid background color that provides sufficient contrast and legibility
Jeff Simmons serves as president of Elanco, the animal health division of Eli Lilly and Company, (NYSE: LLY). As part of this role, he is also a senior vice president and executive officer of Lilly. A global leader with a 60-year track record of growth, Elanco provides comprehensive products and knowledge services to improve animal health, welfare and food animal production with 125 brands in 90 countries.
As the head of Elanco Animal Health for the past decade, Simmons has directed the company’s transformation from a primarily US feed additive company to a premier global player with a balanced and diversified business. During Simmons’ tenure Elanco has tripled in size, created a unique innovation engine, completed 10 acquisitions and built five new businesses, including a $1 billion companion animal business.
In his nearly 30 years with the company, Simmons has held an array of roles, from sales and marketing, to country director in Brazil, area director for West Europe and executive director for North America and Global Research & Development. In these roles, Simmons gained a new perspective on food, agriculture and companionship that has sparked a deep conviction for finding solutions to achieve global food security through a One Health approach. He’s authored white papers on this subject and helped found the Enough Movement, a 30,000-member global community dedicated to building dialogue and finding practical solutions for a food secure world.
The Elanco team is grounded in delivering a higher purpose: Food and Companionship Enriching Life. The team helps animals and pets live healthy, good quality lives. They support the physical, emotional and social well-being of people through a balanced diet rich in protein and the companionship of pets. And, they preserve the health of the planet by helping farmers raise animals more efficiently.
Simmons brings his passions for food security and enabling leaders to life daily through his pursuits with Hatch™ and Edge Mentoring. As the co-founder of Hatch, Simmons and the team have created a unique, donation-free model to deliver sustained food security through protein and partner value. Today, Hatch provides about 45,000 dozen eggs per month to food banks in communities across the country. Simmons also founded Edge Mentoring, one of the fastest-growing mentorship organizations in the country with more than 700 members in over 40 states, several countries and multiple continents. Edge’s purpose is to equip and accelerate whole-life excellence in the leaders of today and tomorrow.
Simmons has also held a number of leadership positions, including serving as a former board member and chairman of the compensation committee for Chiquita Brands. He has also completed terms as president of the Health for Animals, chairman of the FFA Foundation Board and as a board member of Gleaners Food Bank of Indiana.
For more, you can follow Jeff and Elanco on social media @JeffSimmons2050, @Elanco, or view the ENOUGH report at ENOUGHmovement.com.
Ralph Heuser is the vice president of Europe, Middle East and Africa for Elanco Animal Health.
Prior to Elanco, Heuser had previously served as the region Head Europe for Novartis Animal Health. He first worked for Pfizer, starting in 1994, as regional key account manager, where he spent much time on the road and with customers. He says his company car became his office and the intense customer interaction greatly benefited him in later positions in sales, marketing and management.
Heuser then moved to become a farm animal business product manager for Boehringer in 1996 and later joined Novartis as head marketing and sales for the Human Medical Nutrition business (now part of Nestlé). During more than 18 years with Novartis and Novartis Animal Health he served in management positions for various countries in Central Europe as well as in Germany and Australia & New Zealand.He held the role as head of global sales excellence and was appointed Head of Region Europe in 2013.
Heuser studied agricultural economics at the University Bonn, Germany and received a doctorate in macroeconomics from the same university.
Click here for more information on the full Elanco leadership team
Elanco Blog - produced and curated by Elanco Animal Health – features thought, opinion and news on animal health across Europe.
As well as contributions from Elanco colleagues on food sustainability, animal welfare and the human-animal bond, we’re inviting contributions from across the animal health community and the wider food and environmental sectors.
If you have something you’d like to share – whether that’s an article, an idea or simply an issue you feel should have a wider audience, then get in touch at: email@example.com.